Palliative radiotherapy (PRT) is a well-established treatment option for the palliation of symptoms related to advanced cancer. Common indications for PRT include pain and fracture prophylaxis from bone metastases, hemostasis, and neurological symptoms from spinal cord compression and/or brain metastases. Due to possible short term side effects and the fact that radiation often requires several weeks for full effect, many have cautioned its use in patients with a mortality estimate of < 30 days. Recently a large meta-analysis was published in the Green Journal which included 42 studies and 88,516 patients with advanced cancer who received PRT (Kutzko et al. Radiother Oncol. 2022). The primary endpoint was to determine the proportion of patients with advanced cancer who received PRT within 30 days of death. In this meta-analysis, it was reported that 16% (95% CI 14% to 18%) of patients with advanced cancer receiving PRT died within 30 days of treatment. [...]
The ASTRO annual meeting is approaching, and we would like to highlight the palliative care sessions that will be featured. These include 2 educational sessions, 2 scientific sessions, and a science highlights. Congratulations to our many SPRO members who will be involved in these sessions!
SPRO is pleased to offer two awards for individuals who have made notable contributions to the field of palliative radiation oncology through clinical care, patient advocacy, education, or research. Lifetime Service Award This award recognizes an individual whose service to the field over a period of a decade or more has resulted in an indelible transformation and advancement of the field of palliative radiation oncology. Rising Star Award This award recognizes an individual who is either a trainee or within the first two years of an academic appointment whose work shows notable promise to be transformative to the field of palliative radiation oncology. Nominations are considered every year, with awards to be presented at the SPRO meeting during ASTRO Please send your nominations (which can be brief and no more than 500 words), including your name, the nominee’s name, the award you are nominating them for, and a description [...]
Patients with lymphoma have historically been excluded from palliative radiation oncology trials given that these tumors are more radioresponsive than other solid tumors. Though radiation dose/fractionation schemes used to palliate lymphoma are often extrapolated from those used for solid tumors, we highlight here unique considerations for palliation of patients with indolent, non-Hodgkin B-cell lymphomas. FORT (Follicular Radiotherapy Trial), a phase 3 randomized trial, compared whether low-dose radiation therapy (RT) of 4 Gy in 2 fractions was non-inferior in local control to the standard 24 Gy in 12 fractions for patients with either follicular (FL) or marginal zone lymphoma (MZL). Target sites, rather than patients, were randomized 1:1, stratified by histology, treatment intent, and treatment center. The non-inferiority margin for local progression at 2 years was pre-specified as ≤10%, corresponding to a hazard ratio (HR) of 1.37. Patients were treated with involved-field RT, rather than the more recently adopted involved-site RT [...]